Forward-Looking Statement This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusi

Unlocking Immunotherapies for Solid

Cancer Patients Immatics Corporate Presentation, January 2021 Exhibit 99.1

Forward-Looking Statement This

presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any

of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in

this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the

information contained herein to make any decision. Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's

future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections

of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend",

"will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such

forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based

upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors

that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in

the Company's filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the

contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking

statements. No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to

buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of

securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Certain information contained in this Presentation relates to

or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no

guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at

this meeting are strictly confidential and should not be discussed outside your organization.

Two Transformative Treatment

Modalities: Adoptive Cell Therapies and TCR Bispecifics Highly Differentiated Technologies to Identify True Cancer Targets and the Right TCRs Unlocking Immunotherapies for Solid Cancer Patients Strategic Collaborations with World-leading Industry

Limitations of Current Immunotherapies

in Solid Cancer Patients Driven by a Lack of Known Cancer-specific Targets 1 Chalmers et al., 2017; 2SEER Cancer Statistics Review, 1975-2017, Estimated New Cancer Cases for 2020 Checkpoint inhibitors mainly effective in tumors with high

mutational burden minority of all cancers1 CAR-T mainly effective in hematological malignancies minority of all cancers2 Solid tumors limited established treatments & high medical need majority of all cancers Most cancer patients do not benefit

from current immuno-oncology approaches Intro

Unlocking Immunotherapies for Solid

Cancer Patients by Intracellular Cancer Targets and Matching Right T cell Receptors (TCRs) Modified from Chandran et al., 2019 Intro

The Immatics Approach to Disrupt

Current Tumor Treatment Paradigms Based on 5 Defined Principals True Cancer Targets & Matching Right TCRs Targeted Approach in Two Distinct Modalities: Adoptive Cell Therapy & TCR Bispecifics Optimized Cell Therapy Products to Enhance T cell

Persistence & Efficacy Disrupting the Tumor Microenvironment by Targeting Stroma Combating Tumor Heterogeneity & Escape through Multi-Target Approach Intro

Immatics' Targeted Approach in

Two Distinct Modalities High tumor burden Lower tumor burden1 1 Patients at earlier stage of disease, de-bulked tumors, or late-stage patients with reduced tumor burden Specialized Centers All Hospitals & Out-Patient Intro

Immatics' Pipeline Modality

Product Candidate Status Preclinical Phase 1a1 Phase 1b1 Phase 2 Phase 3 Autologous ACT ACTengine IMA201 (MAGEA4/8) Proprietary ACTengine IMA202 (MAGEA1) Proprietary ACTengine IMA203 (PRAME) Proprietary ACTengine IMA204

(COL6A3) Proprietary Autologous TCR-T ACT programs (Undisclosed) ACT programs (Undisclosed) Allogeneic ACT ACTallo IMA301 (Undisclosed) Proprietary Bispecifics TCER IMA401 (MAGEA4/8) Proprietary TCER IMA402 (Undisclosed)

Proprietary Bispecific programs (Undisclosed) Bispecific programs (Undisclosed) 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion Intro

Strategic Collaborations with

World-leading Industry Players Validating Immatics' Differentiated Technologies and Expertise 2017 Bispecific Cancer Immunotherapies $30m upfront 2 Immatics targets 2018 Bispecific Cancer Immunotherapies $54m upfront 3 Immatics targets 2019

Adoptive Cell Therapies $75m upfront 3 Immatics targets Opt-in Rights for BMS 2020 Adoptive Cell Therapies $50m upfront 2 Immatics targets Each of the 10 partnered Immatics programs may be eligible for >$500m aggregate milestone payments per

program Tiered royalties per program Co-Promotion Option Co-Devel./Co-Fund Option Co-Development Option Intro

Upcoming R&D Milestones in 2021

1H 2021 2H 2021 ACTengine IMA201, 202, 203: Initial Ph1a dose escalation read-out IMA201, 203: Additional Ph1a read-out IMA204 IND submission TCER IMA401 IND submission Intro IMA202: Initial Ph1b dose expansion read-out IMA402 Start GMP

manufacturing activities

Adoptive Cell Therapy

Immatics' TCR-T Approach 1 IMA201, IMA202 and IMA203 in Ph1 clinical trials, IMA204 IND expected in 2H 2021 ACTengine Key Differentiation Points High-density peptide targets designed for enhanced efficacy and matching highly specific

TCRs with reduced risk for off-target toxicity Optimized cell therapy product through short 1-week manufacturing delivering younger T cells designed for enhanced engraftment, persistence and tumor infiltration Single screening assay IMADetect

to efficiently shuttle patients to one of 4 different programs2 reducing patient attrition IMA203 PRAME IMA204 COL6A3 IMA201 MAGEA4/8 IMA202 MAGEA1 Cancer target profiling via IMADetect Cancer patients 1 3 Antigen 4 Expression 2 x x x

Manufacturing of matching T cell product1 ACT HLA-A*02 positive

ACTengine IMA201, IMA202 &

IMA203 - Ongoing Clinical Trials ACT 1 Defined as copy number per cell determined by mass spectrometry-based AbsQuant technology; 2 Applying XPRESIDENT -guided off-target toxicity and similar peptide screening designed for reduced

cross-reactivity; 3 Lymphodepletion 40 mg/m2 fludarabine and 500 mg/m2 cyclophosphamide daily for 4 days. IMA201 (MAGEA4/8) IMA202 (MAGEA1) IMA203 (PRAME) Target HLA-A*02-presented peptide identified and validated by XPRESIDENT mass

spectrometry platform Target Density1 100-1,000 50-900 100-1,000 T cell receptor (TCR) High-affinity TCR identified and validated by XCEPTOR platform2 High-affinity natural TCR High-affinity natural TCR with preferential pairing of

/ chain Patients Target positive, HLA-A02+ advanced cancer patients relapsing from prior therapies enrolled to all-comers trials Target positive, HLA-A02+ patients enrolled to an all-comers trial Treatment Infusion of engineered T

cells followed by IL-2 administration after lymphodepletion3 Infusion of engineered T cells with a proprietary TCR targeting PRAME (IMA203) after lymphodepletion followed by IL-2 administration* Selected Indications sqNSCLC, HNSCC, bladder cancer

HCC, sqNSCLC, melanoma Ovarian cancer, uterine cancer, melanoma, sqNSCLC Endpoints Primary: Safety and Tolerability; Secondary: T cell Persistence, Tumor Response Safety Current Status Phase 1a (Dose Escalation); Enrolling patients in US and

Europe Phase 1a Dose Escalation Number of patients 2+2 trial design N=6-9 patients 2+2 trial design N=6-9 patients 3+3 trial design N=12-15 patients Phase 1b Dose Expansion Number of patients N=10 additional patients N=10 additional patients N=12

Optimized Cell Therapy Products to

Enhance T cell Persistence & Efficacy Proprietary Manufacturing Process, designed to reduce manufacturing process to approx. 1 week shorten vein-to-vein time generate younger T cells with increased proliferative capacity improve engraftment and

persistence in patients while utilizing smaller doses Current Proprietary Manufacturing Protocol ACT In-house state-of-the-art cGMP Facility1 Manufacturing by Immatics personnel Maximum capacity: 48 manufacturing runs/month Substantial in-house

process development expertise 1 Exclusive access through collaboration with UT Health, Houston, TX Expedited QC testing (~1 week) Manufacturing time (~1 week) QC testing (Full sterility, 2 weeks) Manufacturing time (~1 week) Commercial

ACTengine expected ~2 weeks ACTengine IMA200 series: ~3 weeks Leukapheresis Infusion-Ready

Early Data in ACTengine Trials

Pointing Towards Favorable Engraftment Next Update: Combined initial data read-out expected in 1Q 20212 Molecular Immunomonitoring in Blood 201 Pt #1 202 Pt #1 203 Pt #1 202 Pt #2 IMA202 Pt#2 IMA203 Pt#1 Persistence of target-specific T cells over

4+ week observation period in 4/4 patients Post-treatment tumor biopsies analysis suggests infiltration of target-specific T cells into tumor T cell Persistence Tumor Infiltration 1 Dose level 1: ~50m/m2 target-specific T cells; 2 Data update is

expected to contain safety, biological efficacy and tumor response data. All trials are expected to recruit patients into the dose escalation phase of the trials, clearance of dose level 2 expected in at least one trial Molecular Immunomonitoring in

Tumor IMA202 Patient #2, IMA203 Patient #1 Data Read-out January 2020 - 4 Patients Treated with IMA201, IMA202 and IMA203 at Lowest Dose1 ACT Cellular Immunomonitoring in Blood IMA203 Patient #1 High frequencies (up to 45%) of persisting

circulating target-specific T cells observed at lowest infused dose T cell Frequency

IMA204 - Disrupting the Tumor

Microenvironment by Targeting Stroma Complete Tumor Eradication in vitro & in vivo1 by Affinity-enhanced IMA204 TCR Candidates One IMA204 TCR candidate leads to full functionality of both CD8 and CD4 T cells Control TCR2 Double mut. TCR1 Single

mut. D7 D16 D22 D29 1 In vivo data by Jim Riley, University of Pennsylvania, control: non-transduced T cells. TCR avidity and specificity data not shown, available in IMA204 presentation on Immatics website. COL6A3 exon 6 prevalently expressed at

high target density in tumor stroma across many solid cancers Final preclinical safety evaluation of two candidate TCRs ongoing IMA204 IND submission expected 2021 Stroma cells Tumor cells Stroma Target (COL6A3 exon 6) in Ovarian Cancer sample

Example of a Tumor Target in same Ovarian Cancer sample Next-gen ACT

ACTallo IMA301 - Towards

Off-the-shelf ACT Effective Redirection of T cells Using TCR T cell collection from healthy donor Off-the-shelf product Transduction Expansion Proprietary manufacturing protocol delivering robust expansion of

T cells with the potential for hundreds of doses from one single donor leukapheresis Off-the-shelf cell therapy, applicable without need for personalized manufacturing and not relying on potentially encumbered immune system of patient

High potency: TCR transduced T cells show similar anti-tumor activity to T cells Proprietary single lentiviral vector system (4-in-1 construct) including TCR and CD8 alpha & beta chains ACTallo Immatics'

Allogeneic ACT Approach IND filing targeted 2022 Next-gen ACT T cells are abundant, show intrinsic anti-tumor activity, naturally infiltrate solid tumors and do not cause graft-vs-host disease

Combating Tumor Heterogeneity &

Escape through Multi-Target Approach A Multi-Step Approach towards Highly Personalized Multi-TCR-T Therapy ACTolog ACTengine TCR-T Personalized Multi-TCR-T 1 2 3 Combination Trial ACTengine Multi-TCR-T 4 >200 prioritized

XPRESIDENT targets Immatics TCR Warehouse Mission to treat every patient ACTolog headline data presented at annual SITC conference available on the Immatics website HLA Targets T cells Status Objective 1 HLA-A2 Multiple Endogenous

Completed Demonstrate feasibility of multi-target concept 2 HLA-A2 Single Genetically engineered 3 trials ongoing Deliver significant clinical benefit for patients with certain tumor types 3 HLA-A2 Two Genetically engineered Mid-Term Perspective

Expand spectrum of tumor types and increase response durability 4 Multiple Multiple Genetically engineered Long-Term Perspective Treat every patient regardless of tumor and HLA type 1 2 3 4 Initial Warehouse Next-gen ACT

TCR Bispecifics Off-the-shelf Biologics Linking Immune Cells to Tumor Cells TCER

Proprietary TCR Bispecific Format TCER T cell recruiting antibody pHLA targeting TCR Fc domain (silenced) with KiH technology TCER Potency and stability of proprietary TCER format is superior to six alternative TCR Bispecific

formats1 1 Based on comparative preclinical testing

Preclinical POC for First TCER

Program IMA401 TCER IMA401 Targeting MAGEA4/8 Results in Tumor Eradication of Established Tumors * TCER Study day -14: transplantation of tumor cells Study day 0: human PBMC transplantation & start of IMA401 weekly treatment

Patient-Derived Tumor Model2 Preclinical Proof-of-Concept Data: High affinity TCR (2 nM) after >10,000-fold affinity-maturation via yeast display High potency at low concentrations in vitro and in vivo in two independent xenograft tumor models

(NSCLC and melanoma)1 Distinguished specificity & broad therapeutic window ( 1,000-fold concentration difference between tumor vs. healthy cell reactivity) Favorable pharmacokinetics with 10-11 days terminal half-life in mice Favorable

CMC Characteristics: Positive purity & stability characteristics with high production yields (2-4 g/l) Following scientific advice with German regulatory authority1, GMP CMC development is on track for IMA401 IND submission YE 2021 1

Equivalent to FDA pre-IND Meeting; 2 Patient-derived LXFA 1012 (NSCLC, adenocarcinoma) tumor xenograft model in NOG mice; additional data from cell line-derived Hs695T (melanoma cell line) tumor xenograft model in NOG mice showing similar data not

True Cancer Targets & Matching

Right TCRs True Targets - expressed on cancer but not or to far lower extent on normal tissue Minimizing risk for on-target toxicity Right TCRs - highly specific and high affinity as outcome of stringent development process Minimizing risk for

off-target toxicity (TCR cross-reactivity) + Right TCR via XCEPTOR TCR Discovery Platform True Target via XPRESIDENT Target Discovery Platform Technology

XPRESIDENT - Discovery

of True Cancer Targets Quantitative, Ultra-Sensitive Mass Spectrometry Expertise Developed over Two Decades >400 million MS/MS spectra >20,000 experiments >8,000 peptides filed for patent >2,000 cancer & normal tissues analyzed by

Quantitative, Ultra-Sensitive Mass Spectrometry Unbiased Identification & characterization of the most relevant1 pHLA targets in the peptide universe pHLA Database based on primary tissues Secured by extensive patent estate >200 prioritized

targets 1 Target expression on cancer tissue with high target levels per tumor cell but not or to a far lower extent on normal tissues 200 Prioritized Targets grouped in 3 Target Classes: Well known and characterized parent protein e.g. MAGE family